# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT CO M BINATIO N TEMPLATE

A. 510(k) Number: k122181   
B. Purpose for Submission: New device   
C. Measurand: Capillary whole blood glucose from the finger   
D. Type of Test: Quantitative amperometric (glucose oxidase)   
E. Applicant: Visgeneer Inc.   
F. Proprietary and Established Names: eBchek Blood Glucose Monitoring System

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1345, Glucose test system 21 CFR 862.1660, Quality Control Material (assayed and unassayed)

2. Classification: Class II, Class I (Reserved)

3. Product code: NBW, System, Test, Blood Glucose, Over The Counter CGA, Glucose Oxidase, Glucose JJX, Quality Control Material

4. Panel: Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): See Indications for Use below.

2. Indication(s) for use:

The eBchek Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips. The eBchek Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.

The eBchek Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The eBchek Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes mellitus or for neonatal use. The eBchek Glucose Meter contains some speaking functions, but is not intended for use by the visually impaired.

eBchek Blood Glucose Test Strips are for use with the eBchek Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips.

eB-series Control Solutions are for use with the eBchek Blood Glucose Meter and eBchek Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.

3. Special conditions for use statement(s):

· For in vitro diagnostic use only   
· For over-the-counter use   
• For single-person use only.   
• Not intended for use on neonates   
• Not for the diagnosis of or screening for diabetes mellitus   
• Not for use on patients who are dehydrated, hypotensive, in shock, or for individuals in hyperglycemic-hyperosmolar state, with or without ketosis. • Critically ill patients should not be tested with a blood glucose meter. • Not intended for alternative site testing

4. Special instrument requirements:

# eBchek Blood Glucose Meter

# I. Device Description:

The eBchek Blood Glucose Monitoring System consists of the eBchek Blood Glucose Meter, eBchek Blood Glucose Test Strips, Lancing device, Lancets, Code card, two AAA Batteries, User’s Manual, and Carrying Case. eB-series Control Solutions (Level 1 and Level 2 are available but sold separately.

Each test strip is single use and must be replaced with a new strip for additional readings. A calibration card is provided with each batch of test strips to calibrate the meter for that batch. No further calibrations are required of the user.

The eB-series Control Solutions contain a known amount of glucose that reacts with eBchek Test Strips. Two different concentrations of eB-series control solutions, Level 1 and Level 2 , are used to check if the meter and test strips are working together properly and that users are performing the test correctly. The test result using control solution should fall within an expected range of results printed on the vial of test strips.

The eBchek Blood Glucose Meter has a speaker function but is not intended for use by the visually impaired.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Visgeneer eBsensor Blood Glucose Monitoring System (Model: eB-G)

2. Predicate 510(k) number(s): k062555

3. Comparison with predicate:

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate DeviceeBchekBlood GlucoseMonitoring System</td><td colspan="1" rowspan="1">Predicate Device(k062555)eBsensor (eB-G)Blood GlucoseMonitoring System</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">The System is used forthe quantitativemeasurement of glucosein fresh capillary wholeblood from thefingertips. It is used bypeople with diabetes, asan aid to monitor theeffectiveness ofdiabetes control. Itshould not be used forthe diagnosis of orscreening for diabetesmellitus and is not foruse on neonates.Testing is for in vitrodiagnostic use only.</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Electrochemicalbiosensor with carbonelectrodes</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Capillary whole blood</td></tr><tr><td colspan="1" rowspan="1">Measurement unit</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">mg/dL or mmol/L</td></tr><tr><td colspan="1" rowspan="1">Enzyme</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Glucose oxidase</td></tr><tr><td colspan="1" rowspan="1">Control Solution</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">eB-series controlsolution (D-glucose,two differentconcentrations at 100and 300 mg/dL)</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Code card required foreach lot of test strips</td></tr><tr><td colspan="1" rowspan="1">Strip Dimension</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">7.9 mm x32 mm</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">CandidateDeviceeBchek (eB-S01)Blood GlucoseMonitoring System</td><td colspan="1" rowspan="1">Predicate Device(k062555)eBsensor (eB-G)Blood GlucoseMonitoring System</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Similarities (cont)</td></tr><tr><td colspan="1" rowspan="1">Data Output</td><td colspan="1" rowspan="1">RS232 PC Interface</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Battery Power</td><td colspan="1" rowspan="1">Two 1.5 V AAA batteries</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Operating TemperatureRange</td><td colspan="1" rowspan="1">50 - 104° F (10 - 40° C)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Operating HumidityRange</td><td colspan="1" rowspan="1">10 - 85% RH</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate DeviceeBchek (eB-S01)Blood GlucoseMonitoring System</td><td colspan="1" rowspan="1">Predicate Device(k062555)eBsensor (eB-G)Blood GlucoseMonitoring System</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Single patient</td><td colspan="1" rowspan="1">Single patient andHealthcareProfessionals</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">0.5 uL</td><td colspan="1" rowspan="1">2.5 uL</td></tr><tr><td colspan="1" rowspan="1">Measuring Time</td><td colspan="1" rowspan="1">5 seconds</td><td colspan="1" rowspan="1">10 seconds</td></tr><tr><td colspan="1" rowspan="1">Hematocrit Range</td><td colspan="1" rowspan="1">20 - 60%</td><td colspan="1" rowspan="1">30 - 55%</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">20 - 600 mg/dL(1.1 - 33.3 mmol/L)</td><td colspan="1" rowspan="1">30 - 600 mg/dL(1.6 - 33.3 mmol/L)</td></tr><tr><td colspan="1" rowspan="1">Slot location</td><td colspan="1" rowspan="1">Bottom</td><td colspan="1" rowspan="1">Top</td></tr><tr><td colspan="1" rowspan="1">Glucose Average</td><td colspan="1" rowspan="1">7, 14 and 28 days</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1">Memory Storage</td><td colspan="1" rowspan="1">450 blood glucose result</td><td colspan="1" rowspan="1">70 blood glucose results</td></tr><tr><td colspan="1" rowspan="1">Speaking Function</td><td colspan="1" rowspan="1">English/Chinese</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1">Meter Dimensions</td><td colspan="1" rowspan="1">95 mm x 55 mm x 18.5 mm</td><td colspan="1" rowspan="1">87 mm x 60 mm x 21mm</td></tr><tr><td colspan="1" rowspan="1">Meter Weight</td><td colspan="1" rowspan="1">85 g</td><td colspan="1" rowspan="1">75 g</td></tr></table>

# K. Standard/Guidance Document Referenced:

EN 61326-1:2006: Electrical equipment for measurement, control, and lab use. EMC requirements: General requirements

EN 61326-2:2006: Electrical equipment for measurement, control and laboratory use - EMC requirements - Part 2-3: Particular requirements - Test configuration, operational conditions and performance criteria for transducers with integrated or remote signal conditioning"

EN 61010-1:2001 Safety requirements for electrical equipment for measurement, control and lab use - Part 1: General requirements

ISO 15197:2003: In Vitro Diagnostic Test Systems—Requirements for Blood Glucose Test Systems for Self Managing Diabetes Mellitus.

# L. Test Principle:

The eBchek Blood Glucose Monitoring System uses electrochemical methodologies to quantitatively measure blood glucose levels by amperometry. The device detects the current produced from oxidation of blood glucose by the enzyme glucose oxidase impregnated in the test strip. The electrons generated during this reaction are transferred from the blood to the electrodes. The magnitude of the resultant current is proportional to the concentration of glucose in the specimen and the signal is converted into a readout displayed on the meter.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

# a. Precision/Reproducibility:

The repeatability study was performed with three test strip lots and 10 meters using venous blood samples spiked to five different concentrations that covered the measuring range of the device. Each sample was tested 10 times for a total n of 150 (5 concentrations $\textbf { \scriptsize x } 1 0$ replicates x 3 strip lots) .The final glucose concentrations for the blood samples were confirmed by YSI. The blood samples had hematocrit levels of $3 5 - 5 0 \%$ . Results are summarized below:

# Within Day Precision:

Lot 1   

<table><tr><td rowspan=1 colspan=1>Level/Ranges(mg/dL)</td><td rowspan=1 colspan=1>Numberof Tests</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>StandardDeviation(mg/dL)</td><td rowspan=1 colspan=1>Coefficient ofVariation(%)</td></tr><tr><td rowspan=1 colspan=1>Level 1 (30-50)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>46.8</td><td rowspan=1 colspan=1>2.58</td><td rowspan=1 colspan=1>5.51</td></tr><tr><td rowspan=1 colspan=1>Level 2 (51-110)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>102.3</td><td rowspan=1 colspan=1>3.98</td><td rowspan=1 colspan=1>3.89</td></tr><tr><td rowspan=1 colspan=1>Level 3 (111-150)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>143.5</td><td rowspan=1 colspan=1>4.64</td><td rowspan=1 colspan=1>3.24</td></tr><tr><td rowspan=1 colspan=1>Level 4 (151-250)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>223.6</td><td rowspan=1 colspan=1>7.02</td><td rowspan=1 colspan=1>3.14</td></tr><tr><td rowspan=1 colspan=1>Level 5 (251-400)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>351.7</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>3.13</td></tr></table>

Lot 2   

<table><tr><td rowspan=1 colspan=1>Level/Ranges(mg/dL)</td><td rowspan=1 colspan=1>Numberof Tests</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>StandardDeviation(mg/dL)</td><td rowspan=1 colspan=1>Coefficientof Variation(%)</td></tr><tr><td rowspan=1 colspan=1>Level 1 (30-50)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>47.0</td><td rowspan=1 colspan=1>2.38</td><td rowspan=1 colspan=1>5.08</td></tr><tr><td rowspan=1 colspan=1>Level 2 (51-110)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>102.1</td><td rowspan=1 colspan=1>3.39</td><td rowspan=1 colspan=1>3.32</td></tr><tr><td rowspan=1 colspan=1>Level 3 (111-150)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>142.4</td><td rowspan=1 colspan=1>4.64</td><td rowspan=1 colspan=1>3.26</td></tr><tr><td rowspan=1 colspan=1>Level 4 (151-250)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>223.3</td><td rowspan=1 colspan=1>7.80</td><td rowspan=1 colspan=1>3.49</td></tr><tr><td rowspan=1 colspan=1>Level 5 (251-400)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>352.5</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>3.52</td></tr></table>

Lot 3   

<table><tr><td rowspan=1 colspan=1>Level/Ranges(mg/dL)</td><td rowspan=1 colspan=1>Numberof Tests</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>StandardDeviation(mg/dL)</td><td rowspan=1 colspan=1>Coefficientof Variation(%)</td></tr><tr><td rowspan=1 colspan=1>Level 1 (30-50)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>47.0</td><td rowspan=1 colspan=1>2.57</td><td rowspan=1 colspan=1>5.47</td></tr><tr><td rowspan=1 colspan=1>Level 2 (51-110)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>102.4</td><td rowspan=1 colspan=1>3.55</td><td rowspan=1 colspan=1>3.47</td></tr><tr><td rowspan=1 colspan=1>Level 3 (111-150)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>143.3</td><td rowspan=1 colspan=1>4.80</td><td rowspan=1 colspan=1>3.35</td></tr><tr><td rowspan=1 colspan=1>Level 4 (151-250)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>222.6</td><td rowspan=1 colspan=1>8.49</td><td rowspan=1 colspan=1>3.81</td></tr><tr><td rowspan=1 colspan=1>Level 5 (251-400)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>352.4</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>3.15</td></tr></table>

Intermediate precision studies were performed with three test strip lots and 10 meters analyzing 3 glucose control solutions for a 10 day period. The test samples had hematocrit levels of $30 \% { - } 5 0 \%$ . Results are

summarized below:

# Intermediate precision

Lot 1   

<table><tr><td rowspan=1 colspan=1>Level/Ranges(mg/dL)</td><td rowspan=1 colspan=1>Numberof Tests</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>StandardDeviation(mg/dL)</td><td rowspan=1 colspan=1>Coefficientof Variation(%)</td></tr><tr><td rowspan=1 colspan=1>Level 1 (30-50)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>44.2</td><td rowspan=1 colspan=1>2.58</td><td rowspan=1 colspan=1>5.85</td></tr><tr><td rowspan=1 colspan=1>Level 2 (96-144)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>133.0</td><td rowspan=1 colspan=1>4.51</td><td rowspan=1 colspan=1>3.39</td></tr><tr><td rowspan=1 colspan=1>Level 3 (280-420)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>365.3</td><td rowspan=1 colspan=1>7.20</td><td rowspan=1 colspan=1>1.97</td></tr></table>

Lot 2   

<table><tr><td rowspan=1 colspan=1>Level/Ranges(mg/dL)</td><td rowspan=1 colspan=1>Numberof Tests</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>StandardDeviation(mg/dL)</td><td rowspan=1 colspan=1>Coefficientof Variation(%)</td></tr><tr><td rowspan=1 colspan=1>Level 1 (30-50)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>43.8</td><td rowspan=1 colspan=1>2.88</td><td rowspan=1 colspan=1>6.57</td></tr><tr><td rowspan=1 colspan=1>Level 2(96-144)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>133.9</td><td rowspan=1 colspan=1>4.75</td><td rowspan=1 colspan=1>3.54</td></tr><tr><td rowspan=1 colspan=1>Level 3 (280-420)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>362.1</td><td rowspan=1 colspan=1>8.95</td><td rowspan=1 colspan=1>2.47</td></tr></table>

Lot 3   

<table><tr><td rowspan=1 colspan=1>Level/Ranges(mg/dL)</td><td rowspan=1 colspan=1>Numberof Tests</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>StandardDeviation(mg/dL)</td><td rowspan=1 colspan=1>Coefficientof Variation(%)</td></tr><tr><td rowspan=1 colspan=1>Level 1 (30-50)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>45.0</td><td rowspan=1 colspan=1>2.74</td><td rowspan=1 colspan=1>6.09</td></tr><tr><td rowspan=1 colspan=1>Level 2(96-144)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>133.9</td><td rowspan=1 colspan=1>3.87</td><td rowspan=1 colspan=1>2.89</td></tr><tr><td rowspan=1 colspan=1>Level 3 (280-420)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>362.8</td><td rowspan=1 colspan=1>9.38</td><td rowspan=1 colspan=1>2.58</td></tr></table>

# b. Linearity/assay reportable range:

Linearity was evaluated using venous whole blood samples spiked with 10 different concentrations of glucose ranging in concentration from 14 - $6 3 3 \mathrm { m g / d L }$ , as measured by the YSI reference method. The blood samples had hematocrit levels of $3 5 - 5 0 \%$ . The data was collected in singlicate with ten meters over six runs $\mathrm { \Delta } \ln { = 6 0 }$ for each concentration). Results are summarized below:

<table><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>1.0162</td><td rowspan=1 colspan=1>4.6032</td><td rowspan=1 colspan=1>0.9986</td></tr></table>

The study results support the sponsor’s claimed glucose measurement range of $2 0 - 6 0 0 \mathrm { m g / d L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability

This assay is traceable to the YSI method and NIST material SRM965.

Stability - eB-series Controls:

Stability for the $e B \cdot$ -series Controls was established when the controls were previously cleared under k062555 with the name eBsensor Control Solutions.

Stability – eBchek Glucose Test Strips

Opened vial test strip stability was evaluated in real-time and accelerated studies. Protocols and acceptance criteria were reviewed and found to be acceptable. The data from these studies supports the claimed open vial stability of 90 days when stored at $4 { - } 3 0 ^ { \circ } \mathrm { C }$ and $10 - 8 5 \%$ relative humidity

Real time studies to evaluate the shelf life (closed-vial) stability of the test strips were conducted. Protocols and acceptance criteria were reviewed and found to be acceptable. The data from these studies supports the claimed closed vial stability of two years when stored $4 { - } 3 0 ^ { \circ } \mathrm { C }$ and $10 - 8 5 \%$ relative humidity.

This information is provided in the labeling of the test strips and control materials.

# d. Detection limit:

The measuring range of the device is $2 0 - 6 0 0 \mathrm { m g / d L }$ . This range was validated by the linearity study (M.1.b).

# e. Analytical specificity:

Interference studies for endogenous and exogenous studies were conducted on 10 eBchek meters, with three lots of test strips using venous blood samples. Five glucose concentrations covering the measuring range of the device were analyzed. Potential interference was evaluated for 25 common endogenous and exogenous potential interferents at two concentrations (low and high) as recommended in CLSI EP7-A guideline. Significant interference is defined as a bias $\geq \pm \ : 1 0 \ : \%$ from the control group as measured by the reference method.

The sponsor claims no significant interference from the following substances at the concentrations shown in the table below:

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Concentration with&lt;10% interference(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Tolbutamide</td><td rowspan=1 colspan=1>64</td></tr><tr><td rowspan=1 colspan=1>Dopamine</td><td rowspan=1 colspan=1>0.07</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Salicylic acid</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Ketoprofen</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Diclofenac</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Indomethacin</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Amiloride</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1>Colchicine</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Atenolol</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>3000</td></tr><tr><td rowspan=1 colspan=1>L-Dopa</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Methyl-Dopa</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Maltose</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Xylose</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Tolazamide</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>Uric acid</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500</td></tr></table>

In their labeling the sponsor states that abnormally high concentrations of Ascorbic acid, Creatinine, Uric acid, Bilirubin, Acetaminophen, Dopamine, Methyl-Dopa, and other reducing substances may cause inaccurate results.

f. Assay cut-ff: Not applicable.

2 Comparison studies:

a. Method comparison with predicate device:

# System Accuracy:

To assess system accuracy, results from the candidate device were compared to the YSI 2300 reference method.. One hundred and two (102) fingerstick capillary blood samples with glucose concentrations ranging from 43to $5 9 2 \mathrm { m g / d L }$ were

analyzed by the candidate device and the reference method. One sample was spiked to achieve high glucose levels. The results of linear regression analysis are as follows:

$$
\mathbf { y } = 0 . 9 9 8 8 + 1 . 2 0 , \mathrm { r } ^ { 2 } = 0 . 9 9 6 9
$$

Results from the eBchek Blood Glucose Monitoring System compared to the YSI results are as follows:

<table><tr><td rowspan=1 colspan=1>SystemAccuracyEvaluation</td><td rowspan=1 colspan=3>&lt;75 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Strip lot</td><td rowspan=1 colspan=1>Within ± 5 mg/dl</td><td rowspan=1 colspan=1>Within ±10mg/dl</td><td rowspan=1 colspan=1>Within ±15mg/dl</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>3/3 (100%)</td><td rowspan=1 colspan=1>3/3 (100%)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8/8 (100%)</td><td rowspan=1 colspan=1>8/8 (100%)</td><td rowspan=1 colspan=1>8/8 (100%)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4/6 (67%)</td><td rowspan=1 colspan=1>6/6 (100%)</td><td rowspan=1 colspan=1>6/6 (100%)</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>15/17 (88%)</td><td rowspan=1 colspan=1>17/17 (100%)</td><td rowspan=1 colspan=1>17/17 (100%)</td></tr></table>

<table><tr><td rowspan=1 colspan=1>SystemAccuracyEvaluation</td><td rowspan=1 colspan=4>≥ 75 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Strip lot</td><td rowspan=1 colspan=1>Within ± 5 %</td><td rowspan=1 colspan=1>Within ±10 %</td><td rowspan=1 colspan=1>Within ± 15%</td><td rowspan=1 colspan=1>Within ± 20%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>27/29 (93%)</td><td rowspan=1 colspan=1>29/29 (100%)</td><td rowspan=1 colspan=1>29/29 (100%)</td><td rowspan=1 colspan=1>29/29 (100%)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>30/35 (86%)</td><td rowspan=1 colspan=1>35/35 (100%)</td><td rowspan=1 colspan=1>35/35 (100%)</td><td rowspan=1 colspan=1>35/35 (100%)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>17/21 (81%)</td><td rowspan=1 colspan=1>21/21 (100%)</td><td rowspan=1 colspan=1>21/21 (100%)</td><td rowspan=1 colspan=1>21/21 (100%)</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>74/85 (87%)</td><td rowspan=1 colspan=1>85/85 (100%)</td><td rowspan=1 colspan=1>85/85 (100%)</td><td rowspan=1 colspan=1>85/85 (100%)</td></tr></table>

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable

c. Other clinical supportive data (when a. and b. are not applicable):

# User Performance Study:

A user study was conducted with 150 volunteer lay users who tested his or her own blood samples. The study subjects ranged in age from 33 to 89 years and were about equally divided between males and females. There was a range of educational backgrounds but none had any experience with self-testing for glucose. The only training provided was for the participants to read the User Manual. After reading the User Manual in English only, the subjects performed their own fingerstick without any practice tests and tested their blood glucose using the Visgineer system. Immediately afterwards, a technician collected another fingerstick sample to be tested using the Visgineer system. Finally, a capillary blood sample from the finger was collected and analyzed on the reference analyzer. The samples tested had glucose concentrations ranging from 58 to $4 5 1 \mathrm { m g / d L }$ as measured by the reference method. The results of linear regression analysis are as follows:

Lay-users vs. YSI (fingersticks)

Lay-user’s results compared to the YSI results:   

<table><tr><td rowspan=1 colspan=6>Samples&lt; 75 mg/dL</td></tr><tr><td rowspan=1 colspan=2>Within ± 5 mg/dl</td><td rowspan=1 colspan=2>Within ±10 mg/dl</td><td rowspan=1 colspan=2>Within ± 15 mg/dl</td></tr><tr><td rowspan=1 colspan=2>16/16 (100%)</td><td rowspan=1 colspan=2>16/16 (100%)</td><td rowspan=1 colspan=2>16/16 (100%)</td></tr><tr><td rowspan=1 colspan=6>Samples &gt; 75 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Within ± 5%</td><td rowspan=1 colspan=2>Within ±10%</td><td rowspan=1 colspan=2>Within ± 15%</td><td rowspan=1 colspan=1>Within ± 20%</td></tr><tr><td rowspan=1 colspan=1>120/134 (90%)</td><td rowspan=1 colspan=2>133/134 (99%)</td><td rowspan=1 colspan=2>134/134 (100%)</td><td rowspan=1 colspan=1>134/134 (100%)</td></tr></table>

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

Expected blood glucose levels for people without diabetes (referenced from the American Diabetes Association Position Statement, Diabetes Care Vol. 35, Supplement 1, p. S13 (2012).

<table><tr><td rowspan=1 colspan=1>Time</td><td rowspan=1 colspan=1>Range (mg/dL)</td><td rowspan=1 colspan=1>Range (mmol/L)</td></tr><tr><td rowspan=1 colspan=1>Fasting andbefore meals</td><td rowspan=1 colspan=1>Less than 100 mg/dL</td><td rowspan=1 colspan=1>5.6 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Two hoursafter meals</td><td rowspan=1 colspan=1>Less than 140 mg/dL</td><td rowspan=1 colspan=1>7.8 mmol/dL</td></tr></table>

# N. Instrument Name:

eBchek Blood Glucose Meter

# O. System Descriptions:

1. Modes of Operation:

Each test strip is single use and must be replaced with a new strip for additional readings.

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?

Yes No _X_

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?

Yes No _X_

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes _X__ No _

3. Specimen Identification:

There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.

4. Specimen Sampling and Handling

The glucose test is intended to be used with capillary whole blood from the fingertips only. The whole blood sample is applied directly to the test strip by capillary action.

# 5. Calibration:

The device must be coded with the code card provided with each vial of test strips. No further calibration is required.

6. Quality Control:

Two levels of glucose control solution (Level 1 and Level 2) are available for the eBchek Blood Glucose Monitoring System. The meter cannot automatically recognize the control solution, so the user needs to switch to the control mode for a control solution test so the result will not be stored in the meter memory as a blood glucose result. Recommendations on when to test the control materials are provided in the labeling. An acceptable range for each control level is printed on the test strip vial label. The user is cautioned not to use the meter if the control result falls outside these ranges.

# P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above:

1. Hematocrit Study:

The effect of different hematocrit levels on the accuracy of the device was evaluated on the eBchek Blood Glucose Monitoring System with 5 meters and one test strip lot. Blood samples at 8 hematocrit levels from $20 \%$ to $60 \%$ (20, 30, 35, 40, 45, 50, 55, and $60 \%$ ) were adjusted to 8 concentrations of glucose covering approximately 20 to $6 0 0 \mathrm { m g / d L }$ . Five replicates were tested for each hematocrit level and glucose concentration. Glucose concentrations were compared to YSI. The study results indicate samples with hematocrit from $20 \% - 6 0 \%$ do not cause unacceptable bias with glucose concentrations between $2 0 - 6 0 0 \mathrm { m g / d L }$ .

2. Altitude study:

Venous whole blood samples were spiked with glucose to five target ranges: ${ < } 3 0$ , 30 – 50, 50 – 100, 250 – 350, and $5 0 0 - 6 0 0 ~ \mathrm { m g / d L }$ . Blood glucose target concentrations were verified by the reference YSI glucose analyzer. Glucose measurements were obtained using the eBchek Blood Glucose Monitoring System at an altitude of 8125 ft. The results demonstrate acceptable bias for samples with glucose concentration $\ge 3 5$ $\mathrm { m g / d L }$ ; the results support the claims in the labeling that altitudes up to 8,000 feet have no significant effect on blood glucose measurements from the eBchek Blood Glucose Monitoring System.

3. Sample volume study:

A sample volume study was performed to verify the claimed test strip minimum sample volume Samples were tested at 5 volumes (0.2, 0.3, 0.4, 0.5 and $1 . 0 \mu \mathrm { L }$ ) and values obtained were compared to YSI values. Results support the claimed sample volume of $0 . 5 \mu \mathrm { L }$ .

4. Temperature and humidity studies:

The sponsor performed studies using venous whole blood samples (glucose concentrations 103, 255, and $5 5 2 \mathrm { m g / d L } )$ ) to evaluate the effect of temperatures ranging from $3 9 - 1 0 8 ^ { \circ } \mathrm { F }$ $( 4 - 4 2 ^ { \circ } \mathrm { C } )$ and relative humidity from $1 0 \% - 9 0 \%$ . Meter results were compared to YSI 2300 reference analyzer. Four temperature and humidity combinations were tested including low temperature/low humidity, low temperature/high humidity, high temperature/low humidity and high temperature/high humidity. The results support the claims in the labeling that the system can be used in conditions of $1 0 - 4 0 ^ { \circ } \mathrm { C }$ with relative humidity of $10 - 8 5 \%$

5. Infection Control Studies:

The device is intended for single-patient use. Disinfection efficacy studies were performed using materials that comprise the meter and lancing device by an outside commercial testing laboratory demonstrating complete inactivation of hepatitis B (HBV) with Dispatch Hospital Cleaner Disinfectant Towels with Bleach (EPA Reg No. 56392-8). The sponsor also demonstrated that there was no change in performance or in the external materials of the meter and lancing device up to 260 cleaning and disinfection cycles (one cycle includes one cleaning wipe plus one disinfecting wipe) to simulate 5 years of meter and lancing device use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.

# 6. Electromagnetic Compatibility (EMC) Testing

EMC testing was performed by SGS Taiwan LTD. The testing lab provided a certificate dated Sept 27, 2010 stating that the device met all applicable requirements. Please also see section K above for specific standards related to EMC testing.

7. Flesch-Kincaid readability assessment was conducted and the result show grade level for eBchek user manual, test strip insert and control solution insert were 7.7, 7.4 and 8.1 respectively.

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.